OBJECTIVE: To assess the feasibility of gadolinium-enhanced 64-slice cardiac CT (CCT) for the diagnosis of obstructive coronary artery disease. DESIGN: Comparative prospective study. SETTING: Outpatient Imaging Diagnostic Centre, Diagnóstico Maipú, Buenos Aires, Argentina. PATIENTS: Twenty patients with suspected coronary artery disease. INTERVENTIONS: Gadolinium-enhanced 64-slice CCT was performed before invasive coronary angiography (ICA). MAIN OUTCOME MEASURES: The feasibility of gadolinium-enhanced 64-slice CCT for detection of obstructive coronary artery disease (>50% diameter reduction) was evaluated, using ICA as the 'gold standard'. Mean lumen attenuation, non-calcified and calcified plaques densities were correlated between gadolinium-enhanced CCT studies and iodine-enhanced CCT studies of a control group. Renal function was strictly monitored. RESULTS: Gadolinium-enhanced CCT demonstrated adequate visualisation of 283/289 coronary segments that were evaluable by ICA, 31 of which had >50% luminal stenosis. In per-segment analysis, gadolinium-enhanced CCT showed a sensitivity of 90.3%, specificity of 96.8%, positive predictive value of 77.8% and negative predictive value of 98.8%. The agreement of coronary stenosis between multidetector CT (MDCT) and ICA was 94.1% (272/289). The mean lumen attenuation, non-calcified and calcified plaques densities in gadolinium-enhanced CCT studies were 140.1 Hounsfield units (HU), 51.1 HU and 523.6 HU, whereas in iodine-enhanced CCT studies the values were 354.1 HU, 101.0 HU and 778.5 HU, respectively (p < 0.001). CONCLUSION: Gadolinium-enhanced CCT is a feasible alternative for patients with severe contraindications to iodinated contrast agents referred for MDCT coronary angiography.
OBJECTIVE: To assess the feasibility of gadolinium-enhanced 64-slice cardiac CT (CCT) for the diagnosis of obstructive coronary artery disease. DESIGN: Comparative prospective study. SETTING:Outpatient Imaging Diagnostic Centre, Diagnóstico Maipú, Buenos Aires, Argentina. PATIENTS: Twenty patients with suspected coronary artery disease. INTERVENTIONS:Gadolinium-enhanced 64-slice CCT was performed before invasive coronary angiography (ICA). MAIN OUTCOME MEASURES: The feasibility of gadolinium-enhanced 64-slice CCT for detection of obstructive coronary artery disease (>50% diameter reduction) was evaluated, using ICA as the 'gold standard'. Mean lumen attenuation, non-calcified and calcified plaques densities were correlated between gadolinium-enhanced CCT studies and iodine-enhanced CCT studies of a control group. Renal function was strictly monitored. RESULTS:Gadolinium-enhanced CCT demonstrated adequate visualisation of 283/289 coronary segments that were evaluable by ICA, 31 of which had >50% luminal stenosis. In per-segment analysis, gadolinium-enhanced CCT showed a sensitivity of 90.3%, specificity of 96.8%, positive predictive value of 77.8% and negative predictive value of 98.8%. The agreement of coronary stenosis between multidetector CT (MDCT) and ICA was 94.1% (272/289). The mean lumen attenuation, non-calcified and calcified plaques densities in gadolinium-enhanced CCT studies were 140.1 Hounsfield units (HU), 51.1 HU and 523.6 HU, whereas in iodine-enhanced CCT studies the values were 354.1 HU, 101.0 HU and 778.5 HU, respectively (p < 0.001). CONCLUSION:Gadolinium-enhanced CCT is a feasible alternative for patients with severe contraindications to iodinated contrast agents referred for MDCT coronary angiography.
Authors: Jessica C Hsu; Lenitza M Nieves; Oshra Betzer; Tamar Sadan; Peter B Noël; Rachela Popovtzer; David P Cormode Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2020-05-22
Authors: Yuyang Li; Kian Shaker; Jakob C Larsson; Carmen Vogt; Hans M Hertz; Muhammet S Toprak Journal: Contrast Media Mol Imaging Date: 2018-12-27 Impact factor: 3.161
Authors: Alaa A A Aljabali; Mazhar S Al Zoubi; Khalid M Al-Batanyeh; Ali Al-Radaideh; Mohammad A Obeid; Abeer Al Sharabi; Walhan Alshaer; Bayan AbuFares; Tasnim Al-Zanati; Murtaza M Tambuwala; Naveed Akbar; David J Evans Journal: Beilstein J Nanotechnol Date: 2019-10-07 Impact factor: 3.649